<code id='4D197B58FF'></code><style id='4D197B58FF'></style>
    • <acronym id='4D197B58FF'></acronym>
      <center id='4D197B58FF'><center id='4D197B58FF'><tfoot id='4D197B58FF'></tfoot></center><abbr id='4D197B58FF'><dir id='4D197B58FF'><tfoot id='4D197B58FF'></tfoot><noframes id='4D197B58FF'>

    • <optgroup id='4D197B58FF'><strike id='4D197B58FF'><sup id='4D197B58FF'></sup></strike><code id='4D197B58FF'></code></optgroup>
        1. <b id='4D197B58FF'><label id='4D197B58FF'><select id='4D197B58FF'><dt id='4D197B58FF'><span id='4D197B58FF'></span></dt></select></label></b><u id='4D197B58FF'></u>
          <i id='4D197B58FF'><strike id='4D197B58FF'><tt id='4D197B58FF'><pre id='4D197B58FF'></pre></tt></strike></i>

          knowledge

          knowledge

          author:entertainment    Page View:372
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more
          JPM: CVS says Medicare Advantage patients are impacting profits
          JPM: CVS says Medicare Advantage patients are impacting profits

          WilfredoLee/APMedicareAdvantagememberscontinuetogotothedoctorandgethealthcareproceduresalotmorethanp

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          Novartis is flashing warning signs about its newly acquired myelofibrosis drug

          MollyFerguson/STATCHICAGO—SomethingisoffaboutthewayNovartisistalkingaboutpelabresib,itsnewlyacquired